AtaiBeckley seeks partner for intranasal 5-MeO-DMT (BPL-003) in treatment-resistant depression after AbbVie-Gilgamesh deal boosts pharma interest

Intranasal 5-MeO-DMT (BPL-003) for treatment-resistant depression is at the center of AtaiBeckley’s structured partner search after the AbbVie-Gilgamesh transaction. AtaiBeckley is reportedly holding structured discussions with pharma companies and royalty investors rather than pursuing a full asset sale. The process, first flagged by Bloomberg, is being advised by Jefferies, JP Morgan, and TD Cowen, with talks potentially moving quickly toward an outcome in April. The effort follows renewed outbound and inbound interest in short-acting psychedelic candidates after unsuccessful bidders from the AbbVie-Gilgamesh deal began looking for the next comparable development opportunity.